NCT04439695View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

February 25, 2021

Study Completion Date

July 28, 2021

Conditions
Influenza
Interventions
BIOLOGICAL

Low dose

Low dose of KBP-V001

BIOLOGICAL

Intermediate dose

Intermediate dose of KBP-V001

BIOLOGICAL

High dose

High dose of KBP-V001

BIOLOGICAL

Placebo

Buffered Saline Solution

Trial Locations (1)

68134

Meridian Clinical Research, Omaha

Sponsors

Lead Sponsor

KBio Inc
All Listed Sponsors
lead

KBio Inc

INDUSTRY

NCT04439695 - Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter